Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 17 | 2024 | 579 | 6.550 |
Why?
|
| Dermatology | 6 | 2024 | 40 | 3.700 |
Why?
|
| Skin | 15 | 2024 | 582 | 3.590 |
Why?
|
| Photochemotherapy | 10 | 2024 | 100 | 3.530 |
Why?
|
| Acne Vulgaris | 5 | 2024 | 35 | 3.050 |
Why?
|
| Education, Medical | 4 | 2024 | 243 | 2.550 |
Why?
|
| Keratosis, Actinic | 4 | 2024 | 12 | 2.150 |
Why?
|
| Melanoma | 6 | 2024 | 467 | 2.090 |
Why?
|
| Skin Diseases | 6 | 2024 | 173 | 1.980 |
Why?
|
| Photosensitizing Agents | 9 | 2024 | 50 | 1.900 |
Why?
|
| Dermatitis, Atopic | 3 | 2022 | 55 | 1.570 |
Why?
|
| Mohs Surgery | 4 | 2024 | 24 | 1.540 |
Why?
|
| Nevus, Pigmented | 2 | 2023 | 50 | 1.540 |
Why?
|
| Internship and Residency | 4 | 2021 | 1041 | 1.520 |
Why?
|
| Pigmentation Disorders | 2 | 2019 | 13 | 1.370 |
Why?
|
| Nevus | 3 | 2023 | 15 | 1.340 |
Why?
|
| Skin Aging | 3 | 2024 | 29 | 1.310 |
Why?
|
| Scalp Dermatoses | 2 | 2019 | 10 | 1.300 |
Why?
|
| Humans | 69 | 2024 | 89157 | 1.120 |
Why?
|
| Laser Therapy | 6 | 2024 | 149 | 1.090 |
Why?
|
| Phototherapy | 2 | 2016 | 35 | 1.080 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 359 | 1.050 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 1096 | 1.020 |
Why?
|
| Sunscreening Agents | 1 | 2024 | 8 | 0.960 |
Why?
|
| Melanosis | 1 | 2024 | 5 | 0.940 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 12 | 0.900 |
Why?
|
| Interleukin-4 | 2 | 2021 | 130 | 0.880 |
Why?
|
| Rejuvenation | 3 | 2024 | 20 | 0.870 |
Why?
|
| Aminolevulinic Acid | 3 | 2019 | 22 | 0.860 |
Why?
|
| Vitamin A | 1 | 2022 | 28 | 0.850 |
Why?
|
| Rhinitis, Allergic | 1 | 2022 | 45 | 0.820 |
Why?
|
| Skin Diseases, Genetic | 1 | 2022 | 3 | 0.820 |
Why?
|
| Mouth Mucosa | 2 | 2019 | 67 | 0.810 |
Why?
|
| Urticaria | 1 | 2022 | 14 | 0.810 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2019 | 7 | 0.790 |
Why?
|
| Exanthema | 1 | 2022 | 39 | 0.780 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 322 | 0.750 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.740 |
Why?
|
| Teaching Materials | 1 | 2020 | 14 | 0.730 |
Why?
|
| Dermatologists | 1 | 2020 | 2 | 0.730 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2020 | 8 | 0.730 |
Why?
|
| Drug Eruptions | 2 | 2021 | 34 | 0.730 |
Why?
|
| Ear Neoplasms | 1 | 2020 | 13 | 0.720 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.720 |
Why?
|
| Mucositis | 1 | 2020 | 18 | 0.720 |
Why?
|
| Certification | 1 | 2020 | 61 | 0.720 |
Why?
|
| Private Practice | 1 | 2020 | 11 | 0.710 |
Why?
|
| Career Mobility | 1 | 2020 | 31 | 0.710 |
Why?
|
| SEER Program | 4 | 2021 | 197 | 0.710 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.700 |
Why?
|
| Hyperpigmentation | 2 | 2017 | 5 | 0.700 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 210 | 0.690 |
Why?
|
| Low-Level Light Therapy | 1 | 2019 | 15 | 0.690 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2019 | 2 | 0.690 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2019 | 24 | 0.680 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 532 | 0.680 |
Why?
|
| Silicone Gels | 1 | 2019 | 3 | 0.680 |
Why?
|
| Bacteremia | 1 | 2020 | 102 | 0.670 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 18 | 0.660 |
Why?
|
| Herpes Simplex | 1 | 2020 | 203 | 0.640 |
Why?
|
| Eyelids | 2 | 2016 | 23 | 0.640 |
Why?
|
| MicroRNAs | 2 | 2021 | 551 | 0.640 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2018 | 6 | 0.630 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2412 | 0.620 |
Why?
|
| Pandemics | 2 | 2023 | 771 | 0.610 |
Why?
|
| Pain | 2 | 2019 | 400 | 0.600 |
Why?
|
| Skin Diseases, Infectious | 1 | 2017 | 13 | 0.600 |
Why?
|
| Licensure, Medical | 3 | 2021 | 20 | 0.570 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 198 | 0.560 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 73 | 0.540 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1150 | 0.530 |
Why?
|
| United States | 7 | 2022 | 6965 | 0.530 |
Why?
|
| Pityriasis Rubra Pilaris | 2 | 2019 | 3 | 0.510 |
Why?
|
| Blepharoplasty | 1 | 2015 | 8 | 0.500 |
Why?
|
| Aspergillosis | 1 | 2015 | 41 | 0.500 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 60 | 0.500 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 975 | 0.500 |
Why?
|
| Biological Products | 1 | 2017 | 154 | 0.500 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.500 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.500 |
Why?
|
| Patient Compliance | 1 | 2016 | 230 | 0.480 |
Why?
|
| Asthma | 1 | 2022 | 977 | 0.480 |
Why?
|
| Photoacoustic Techniques | 2 | 2024 | 7 | 0.470 |
Why?
|
| Condylomata Acuminata | 1 | 2014 | 15 | 0.470 |
Why?
|
| Sweet Syndrome | 2 | 2014 | 5 | 0.460 |
Why?
|
| Aged | 12 | 2024 | 19119 | 0.460 |
Why?
|
| Male | 22 | 2024 | 42309 | 0.460 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 45 | 0.450 |
Why?
|
| Skin Pigmentation | 3 | 2024 | 32 | 0.450 |
Why?
|
| Female | 24 | 2024 | 46078 | 0.450 |
Why?
|
| Epidermis | 3 | 2024 | 102 | 0.430 |
Why?
|
| Middle Aged | 14 | 2024 | 25910 | 0.420 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1596 | 0.380 |
Why?
|
| Tomography, Optical Coherence | 4 | 2024 | 136 | 0.370 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8217 | 0.360 |
Why?
|
| Infant | 3 | 2022 | 3149 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2014 | 477 | 0.360 |
Why?
|
| Esthetics | 3 | 2021 | 45 | 0.360 |
Why?
|
| Cicatrix | 2 | 2024 | 68 | 0.350 |
Why?
|
| Retrospective Studies | 5 | 2022 | 9022 | 0.350 |
Why?
|
| Heart Transplantation | 1 | 2015 | 717 | 0.340 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 9 | 0.340 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6794 | 0.340 |
Why?
|
| Dermis | 1 | 2009 | 28 | 0.340 |
Why?
|
| Sarcoidosis | 2 | 2020 | 72 | 0.330 |
Why?
|
| Ultraviolet Therapy | 1 | 2009 | 16 | 0.330 |
Why?
|
| Rare Diseases | 2 | 2019 | 70 | 0.320 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 233 | 0.320 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2024 | 61 | 0.300 |
Why?
|
| Color | 2 | 2019 | 85 | 0.300 |
Why?
|
| Curriculum | 2 | 2021 | 567 | 0.270 |
Why?
|
| Administration, Topical | 2 | 2018 | 96 | 0.270 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1837 | 0.260 |
Why?
|
| Survival Rate | 2 | 2020 | 1890 | 0.260 |
Why?
|
| Cosmetic Techniques | 2 | 2016 | 28 | 0.260 |
Why?
|
| Erythema | 3 | 2022 | 29 | 0.250 |
Why?
|
| Biomarkers | 3 | 2021 | 1763 | 0.240 |
Why?
|
| Age Factors | 2 | 2019 | 1867 | 0.240 |
Why?
|
| Infant, Newborn | 2 | 2022 | 2479 | 0.240 |
Why?
|
| Adult | 11 | 2024 | 26542 | 0.240 |
Why?
|
| Striae Distensae | 1 | 2024 | 1 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 786 | 0.240 |
Why?
|
| Administration, Cutaneous | 1 | 2024 | 60 | 0.230 |
Why?
|
| Patient Care | 1 | 2024 | 102 | 0.220 |
Why?
|
| Video Recording | 1 | 2024 | 203 | 0.220 |
Why?
|
| Health Literacy | 1 | 2024 | 73 | 0.220 |
Why?
|
| Retinoids | 1 | 2022 | 18 | 0.210 |
Why?
|
| Purpura | 2 | 2000 | 8 | 0.210 |
Why?
|
| Varicose Ulcer | 1 | 2022 | 6 | 0.210 |
Why?
|
| Child | 5 | 2022 | 7154 | 0.210 |
Why?
|
| Phenols | 1 | 2022 | 41 | 0.210 |
Why?
|
| Biopsy | 3 | 2023 | 1182 | 0.210 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1710 | 0.210 |
Why?
|
| Hidradenitis | 1 | 2021 | 2 | 0.200 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2021 | 13 | 0.200 |
Why?
|
| Incidence | 2 | 2023 | 1593 | 0.200 |
Why?
|
| Communicable Diseases | 1 | 2022 | 63 | 0.200 |
Why?
|
| Insulin Resistance | 2 | 2021 | 353 | 0.190 |
Why?
|
| Ultrasonography | 1 | 2024 | 711 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 447 | 0.190 |
Why?
|
| Bronchogenic Cyst | 1 | 2021 | 5 | 0.190 |
Why?
|
| Dermoid Cyst | 1 | 2021 | 15 | 0.190 |
Why?
|
| Dermoscopy | 1 | 2020 | 6 | 0.190 |
Why?
|
| Up-Regulation | 2 | 2021 | 727 | 0.190 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2020 | 6 | 0.180 |
Why?
|
| Staphylococcus epidermidis | 1 | 2020 | 15 | 0.180 |
Why?
|
| Ear, External | 1 | 2020 | 26 | 0.180 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2020 | 2 | 0.180 |
Why?
|
| Accreditation | 1 | 2020 | 62 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2020 | 60 | 0.180 |
Why?
|
| Necrosis | 3 | 2015 | 209 | 0.180 |
Why?
|
| Mannose-Binding Lectins | 1 | 2019 | 6 | 0.170 |
Why?
|
| Tattooing | 1 | 2019 | 5 | 0.170 |
Why?
|
| Mutagens | 1 | 2019 | 31 | 0.170 |
Why?
|
| Panuveitis | 1 | 2019 | 2 | 0.170 |
Why?
|
| Mastocytoma, Skin | 1 | 2019 | 1 | 0.170 |
Why?
|
| Protective Factors | 1 | 2019 | 23 | 0.170 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1574 | 0.170 |
Why?
|
| Mastocytoma | 1 | 2019 | 4 | 0.170 |
Why?
|
| Lupus Vulgaris | 1 | 2019 | 4 | 0.170 |
Why?
|
| Corneal Ulcer | 1 | 2019 | 6 | 0.170 |
Why?
|
| Cultural Diversity | 1 | 2020 | 57 | 0.170 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2019 | 4 | 0.170 |
Why?
|
| Scleritis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 277 | 0.170 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 6 | 0.170 |
Why?
|
| S100 Proteins | 1 | 2019 | 51 | 0.170 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 37 | 0.170 |
Why?
|
| Paraproteinemias | 1 | 2019 | 15 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2020 | 335 | 0.170 |
Why?
|
| Lectins, C-Type | 1 | 2019 | 86 | 0.170 |
Why?
|
| Arthralgia | 1 | 2019 | 39 | 0.170 |
Why?
|
| Antigen-Antibody Complex | 1 | 2019 | 87 | 0.170 |
Why?
|
| Simplexvirus | 1 | 2020 | 151 | 0.170 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 510 | 0.160 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 76 | 0.160 |
Why?
|
| Medicare | 1 | 2022 | 424 | 0.160 |
Why?
|
| Minority Groups | 1 | 2020 | 145 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 860 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2000 | 118 | 0.160 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 30 | 0.160 |
Why?
|
| Pain Management | 1 | 2019 | 138 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2019 | 308 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 244 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 540 | 0.150 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 8 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 186 | 0.150 |
Why?
|
| Keratinocytes | 1 | 2018 | 146 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2019 | 466 | 0.150 |
Why?
|
| Wound Healing | 2 | 2019 | 359 | 0.150 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 502 | 0.150 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1997 | 2 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 296 | 0.150 |
Why?
|
| Neutrophils | 3 | 2021 | 308 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 604 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 848 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1709 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 178 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 336 | 0.140 |
Why?
|
| Hospitalization | 1 | 2022 | 876 | 0.140 |
Why?
|
| Nocardia Infections | 1 | 2016 | 5 | 0.140 |
Why?
|
| Onychomycosis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2016 | 1 | 0.140 |
Why?
|
| Doxycycline | 1 | 2016 | 28 | 0.140 |
Why?
|
| Telangiectasis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 398 | 0.130 |
Why?
|
| Hirsutism | 1 | 2016 | 61 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2614 | 0.130 |
Why?
|
| Sex Factors | 1 | 2019 | 1063 | 0.130 |
Why?
|
| Logistic Models | 2 | 2019 | 1213 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 391 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2021 | 780 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2017 | 561 | 0.130 |
Why?
|
| Cosmetics | 1 | 2015 | 7 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 792 | 0.120 |
Why?
|
| Life Change Events | 1 | 2015 | 48 | 0.120 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1798 | 0.120 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 22 | 0.120 |
Why?
|
| Caustics | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cryotherapy | 1 | 2014 | 30 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 123 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2363 | 0.110 |
Why?
|
| Prognosis | 1 | 2021 | 3776 | 0.110 |
Why?
|
| Animals | 7 | 2024 | 27330 | 0.110 |
Why?
|
| Muir-Torre Syndrome | 1 | 2012 | 4 | 0.110 |
Why?
|
| Child Development | 1 | 2015 | 167 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 114 | 0.110 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 25 | 0.110 |
Why?
|
| Risk Factors | 4 | 2019 | 5483 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 251 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 576 | 0.110 |
Why?
|
| Inflammation | 1 | 2018 | 971 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1547 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2014 | 301 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 684 | 0.100 |
Why?
|
| Young Adult | 1 | 2024 | 6294 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 2302 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2553 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 625 | 0.090 |
Why?
|
| Adenoma | 1 | 2012 | 246 | 0.090 |
Why?
|
| HIV Infections | 1 | 2019 | 837 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2021 | 3376 | 0.090 |
Why?
|
| Mice | 2 | 2021 | 11743 | 0.080 |
Why?
|
| Rabbits | 3 | 2000 | 638 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 1848 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 32 | 0.080 |
Why?
|
| Adolescent | 3 | 2017 | 9243 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 966 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2021 | 519 | 0.080 |
Why?
|
| Dermatofibrosarcoma | 1 | 2008 | 13 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 711 | 0.080 |
Why?
|
| Porphyrins | 2 | 1998 | 39 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 739 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 849 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2024 | 192 | 0.060 |
Why?
|
| Support Vector Machine | 1 | 2023 | 25 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 1717 | 0.060 |
Why?
|
| Ulcer | 1 | 2022 | 37 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1855 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 188 | 0.050 |
Why?
|
| Burns | 1 | 2024 | 141 | 0.050 |
Why?
|
| Hair Removal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Sweat Glands | 1 | 2021 | 6 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 37 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2002 | 160 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2021 | 78 | 0.050 |
Why?
|
| Mercaptopurine | 1 | 2021 | 53 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 868 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 1237 | 0.050 |
Why?
|
| Leg Ulcer | 1 | 2001 | 7 | 0.050 |
Why?
|
| Cytarabine | 1 | 2021 | 219 | 0.050 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2001 | 19 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 299 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 251 | 0.050 |
Why?
|
| Pruritus | 1 | 2000 | 29 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 237 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2000 | 94 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 415 | 0.040 |
Why?
|
| Software | 1 | 2024 | 665 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2001 | 184 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2018 | 39 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 4041 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1363 | 0.040 |
Why?
|
| Maximum Allowable Concentration | 1 | 1997 | 2 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 1997 | 19 | 0.040 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1997 | 41 | 0.040 |
Why?
|
| Fluorescence | 1 | 1997 | 103 | 0.040 |
Why?
|
| Edema | 1 | 1997 | 70 | 0.040 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.040 |
Why?
|
| Light | 1 | 1997 | 292 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1142 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1875 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 4281 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 783 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 36 | 0.030 |
Why?
|
| Time Factors | 3 | 2002 | 5331 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 29 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1665 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 170 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2658 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 771 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 948 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1989 | 35 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1989 | 135 | 0.020 |
Why?
|
| Furocoumarins | 1 | 2007 | 2 | 0.020 |
Why?
|
| New Hampshire | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 22 | 0.020 |
Why?
|
| Diet | 1 | 1989 | 442 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 195 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 44 | 0.010 |
Why?
|
| Skin, Artificial | 1 | 2001 | 8 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3721 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 93 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 996 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 293 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 82 | 0.010 |
Why?
|
| Iontophoresis | 1 | 1997 | 9 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 243 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1764 | 0.010 |
Why?
|
| Plant Oils | 1 | 1989 | 9 | 0.010 |
Why?
|
| Occupations | 1 | 1989 | 25 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1989 | 360 | 0.010 |
Why?
|
| Smoking | 1 | 1989 | 621 | 0.000 |
Why?
|